286 related articles for article (PubMed ID: 12874442)
1. Role of advanced glycation end products in diabetic nephropathy.
Forbes JM; Cooper ME; Oldfield MD; Thomas MC
J Am Soc Nephrol; 2003 Aug; 14(8 Suppl 3):S254-8. PubMed ID: 12874442
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation end products and diabetic nephropathy.
Thomas MC; Forbes JM; Cooper ME
Am J Ther; 2005; 12(6):562-72. PubMed ID: 16280650
[TBL] [Abstract][Full Text] [Related]
3. Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.
Jerums G; Panagiotopoulos S; Forbes J; Osicka T; Cooper M
Arch Biochem Biophys; 2003 Nov; 419(1):55-62. PubMed ID: 14568009
[TBL] [Abstract][Full Text] [Related]
4. Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells.
Huang K; Huang J; Xie X; Wang S; Chen C; Shen X; Liu P; Huang H
Free Radic Biol Med; 2013 Dec; 65():528-540. PubMed ID: 23891678
[TBL] [Abstract][Full Text] [Related]
5. Osteomeles schwerinae extracts inhibits the binding to receptors of advanced glycation end products and TGF-β1 expression in mesangial cells under diabetic conditions.
Kim YS; Jung DH; Lee IS; Pyun BJ; Kim JS
Phytomedicine; 2016 Apr; 23(4):388-97. PubMed ID: 27002409
[TBL] [Abstract][Full Text] [Related]
6. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
[TBL] [Abstract][Full Text] [Related]
7. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
Nangaku M; Miyata T; Sada T; Mizuno M; Inagi R; Ueda Y; Ishikawa N; Yuzawa H; Koike H; van Ypersele de Strihou C; Kurokawa K
J Am Soc Nephrol; 2003 May; 14(5):1212-22. PubMed ID: 12707391
[TBL] [Abstract][Full Text] [Related]
8. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes.
Coughlan MT; Forbes JM; Cooper ME
Kidney Int Suppl; 2007 Aug; (106):S54-60. PubMed ID: 17653212
[TBL] [Abstract][Full Text] [Related]
9. Role of AGEs in diabetic nephropathy.
Fukami K; Yamagishi S; Ueda S; Okuda S
Curr Pharm Des; 2008; 14(10):946-52. PubMed ID: 18473844
[TBL] [Abstract][Full Text] [Related]
10. [Molecular bases of diabetic nephropathy].
Lagranha CJ; Fiorino P; Casarini DE; Schaan BD; Irigoyen MC
Arq Bras Endocrinol Metabol; 2007 Aug; 51(6):901-12. PubMed ID: 17934656
[TBL] [Abstract][Full Text] [Related]
11. Advanced glycation end products.
Thomas MC
Contrib Nephrol; 2011; 170():66-74. PubMed ID: 21659759
[TBL] [Abstract][Full Text] [Related]
12. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology.
Wolf G
Eur J Clin Invest; 2004 Dec; 34(12):785-96. PubMed ID: 15606719
[TBL] [Abstract][Full Text] [Related]
13. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
[TBL] [Abstract][Full Text] [Related]
14. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.
Forbes JM; Cooper ME; Thallas V; Burns WC; Thomas MC; Brammar GC; Lee F; Grant SL; Burrell LM; Jerums G; Osicka TM
Diabetes; 2002 Nov; 51(11):3274-82. PubMed ID: 12401719
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
Thallas-Bonke V; Lindschau C; Rizkalla B; Bach LA; Boner G; Meier M; Haller H; Cooper ME; Forbes JM
Diabetes; 2004 Nov; 53(11):2921-30. PubMed ID: 15504973
[TBL] [Abstract][Full Text] [Related]
16. Roles of advanced glycation end-products in the progression of diabetic nephropathy.
Makino H; Shikata K; Kushiro M; Hironaka K; Yamasaki Y; Sugimoto H; Ota Z; Araki N; Horiuchi S
Nephrol Dial Transplant; 1996; 11 Suppl 5():76-80. PubMed ID: 9044313
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end products and diabetic complications.
Stitt AW; Jenkins AJ; Cooper ME
Expert Opin Investig Drugs; 2002 Sep; 11(9):1205-23. PubMed ID: 12225243
[TBL] [Abstract][Full Text] [Related]
18. Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathy.
Forbes JM; Thallas-Bonke V; Cooper ME; Thomas MC
Curr Pharm Des; 2004; 10(27):3361-72. PubMed ID: 15544521
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?
Coughlan MT; Thallas-Bonke V; Pete J; Long DM; Gasser A; Tong DC; Arnstein M; Thorpe SR; Cooper ME; Forbes JM
Endocrinology; 2007 Feb; 148(2):886-95. PubMed ID: 17110423
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy.
Kumar Pasupulati A; Chitra PS; Reddy GB
Biomol Concepts; 2016 Dec; 7(5-6):293-309. PubMed ID: 27816946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
